PITTSBURGH, Pennsylvania — Cognition Therapeutics has raised $1.2 million to further study of its tests and treatments of specific proteins that could detect and stop Alzheimer’s disease.
Cognition focuses on detecting the Abeta proteins found in Alzheimer’s patients that lead to the degeneration in the brain. The company is also developing molecules to block the proteins’ negative results and either stop or reverse Alzheimer’s. The company says its discoveries could also treat other neurodegenerative diseases.
Ogden CAP, LLC lead this Series A funding round, which also included M5Invest Partners, the Pittsburgh Life Sciences Greenhouse and Innovation Works, as well as some individual investors. Ogden CAP and M5Invest are new investors, according to the company.
How Artera is Using Agentic AI to Humanize Patient Care
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
Cognition moved to Pittsburgh about two years ago from California. The advancements developed by the company are licensed from California State University Channel Islands.